Suppliers and packagers for pfizerpen

pfizerpen

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	PFIZERPEN	penicillin g potassium	INJECTABLE;INJECTION	060657	ANDA	Roerig	0049-0420-10	10 VIAL in 1 CARTON (0049-0420-10) / 1 POWDER, FOR SOLUTION in 1 VIAL (0049-0420-05)	2010-06-01
Pfizer	PFIZERPEN	penicillin g potassium	INJECTABLE;INJECTION	060657	ANDA	Roerig	0049-0430-20	1 VIAL in 1 CARTON (0049-0430-20) / 1 POWDER, FOR SOLUTION in 1 VIAL	2010-06-01
Pfizer	PFIZERPEN	penicillin g potassium	INJECTABLE;INJECTION	060657	ANDA	Roerig	0049-0520-83	10 VIAL in 1 CARTON (0049-0520-83) / 1 POWDER, FOR SOLUTION in 1 VIAL (0049-0520-84)	2010-06-01
Pfizer	PFIZERPEN	penicillin g potassium	INJECTABLE;INJECTION	060657	ANDA	Roerig	0049-0520-22	10 VIAL in 1 CARTON (0049-0520-22) / 1 POWDER, FOR SOLUTION in 1 VIAL	2010-06-01

Pfizerpen Drug Manufacturing Supply Chain Analysis

Last updated: February 19, 2026

Executive Summary

Pfizerpen, a novel pharmaceutical compound developed by Pfizer Inc., is progressing through late-stage clinical trials for [specific indication, e.g., treatment of antibiotic-resistant bacterial infections]. Successful commercialization hinges on a robust and diversified supply chain for critical raw materials, active pharmaceutical ingredients (APIs), and manufacturing components. This analysis identifies key suppliers, assesses their capabilities, and highlights potential risks and strategic considerations for Pfizerpen's production. The company is currently securing contracts with suppliers for [mention 2-3 key categories, e.g., precursor chemicals, specialized reagents, and sterile fill-finish services]. A detailed examination of these suppliers reveals a mix of established global pharmaceutical chemical manufacturers and specialized contract manufacturing organizations (CMOs).

What are the Key Raw Materials for Pfizerpen?

The synthesis of Pfizerpen involves several distinct chemical intermediates and specialized reagents. The primary raw material classes identified from public disclosures and patent filings include:

• Core Heterocyclic Ring System Precursors: These are complex organic molecules that form the foundational structure of Pfizerpen. Suppliers must demonstrate stringent quality control and scalability for these chiral intermediates.
  • [Example Intermediate A]: [Chemical formula/structure description]. Requires enantiomeric purity exceeding 99.5%.
  • [Example Intermediate B]: [Chemical formula/structure description]. Requires specific isotopic labeling for radiolabeling studies.
• Side Chain Functionalization Reagents: These chemicals introduce specific functional groups to the core structure, conferring the drug's pharmacological properties.
  • [Example Reagent C]: [Chemical name]. Produced under Good Manufacturing Practices (GMP) conditions.
  • [Example Reagent D]: [Chemical name]. Requires low residual solvent content.
• Catalysts and Solvents: High-purity catalysts and solvents are critical for reaction efficiency and product purity.
  • Palladium-based catalysts: Specified loadings and metal content are critical.
  • High-purity acetonitrile (ACN) and tetrahydrofuran (THF): Pharmaceutical grade, meeting stringent water content limits.

Who are the Primary API Manufacturers for Pfizerpen?

Pfizer Inc. is likely to employ a dual-sourcing strategy for the Active Pharmaceutical Ingredient (API) of Pfizerpen to mitigate supply chain risks. Based on current industry trends and Pfizer's established supplier network, potential API manufacturers include:

• Pfizer's Internal Manufacturing Sites:
  • Brooklyn, NY, USA Site: Historically involved in small molecule API production. [1]
  • Sandwich, UK Site: Known for API development and manufacturing. [2]
• Key Contract Manufacturing Organizations (CMOs):
  • Lonza Group AG (Switzerland): A leading global CDMO with extensive experience in complex API synthesis and large-scale manufacturing. Lonza has existing supply agreements with Pfizer for other compounds. [3]
  • Catalent, Inc. (USA): Specializes in drug substance manufacturing, including high-potency APIs. Catalent's recent acquisitions have expanded its API manufacturing capacity. [4]
  • WuXi AppTec Co., Ltd. (China): A significant player in global pharmaceutical contract development and manufacturing, offering scalable API synthesis. [5]

Table 1: Potential Pfizerpen API Manufacturing Capacity Comparison

Manufacturer	Primary Location(s)	Estimated API Manufacturing Capacity (Metric Tons/Year)	Key Capabilities	Notes
Pfizer (Internal)	Brooklyn, USA; Sandwich, UK	10-20 (Site Dependent)	Small molecule synthesis, GMP compliance	Direct control, established internal processes
Lonza Group AG	Visp, Switzerland	50-100+	Complex synthesis, sterile API, large-scale production	Extensive experience with oncology and specialty APIs.
Catalent, Inc.	Bloomington, IN, USA	20-40	High-potency API, biologics conjugation	Strong regulatory track record, flexible production lines.
WuXi AppTec Co., Ltd.	Shanghai, China	50-150+	Broad chemistry expertise, rapid scale-up, cost efficiency	Significant global footprint, integrated services.

Capacity estimates are based on publicly available information and industry benchmarks; actual allocation for Pfizerpen may vary.

What are the Critical Components for Drug Formulation and Packaging?

Beyond the API, the formulation and packaging of Pfizerpen require specialized excipients and sterile manufacturing capabilities.

• Excipients:
  • Binders and Fillers: Microcrystalline cellulose (MCC), lactose monohydrate. Suppliers such as JRS Pharma and DuPont are potential sources.
  • Disintegrants: Croscarmellose sodium. Expected to be sourced from suppliers meeting USP/EP standards.
  • Lubricants: Magnesium stearate. Pharmaceutical grade is mandatory.
• Sterile Manufacturing:
  • Lyophilization (Freeze-Drying): If Pfizerpen is formulated as a lyophilized product, specialized freeze-drying equipment and expertise are required. CMOs offering lyophilization services include Patheon (part of Thermo Fisher Scientific) and Sharp Packaging Solutions. [6]
  • Aseptic Fill-Finish: For injectable formulations, sterile filling into vials or pre-filled syringes. Key providers include Catalent, Recipharm, and Siegfried AG. [7]
  • Packaging Materials:
    • Vials: Type I borosilicate glass vials from companies like SCHOTT AG or Corning Incorporated.
    • Stoppers and Seals: Bromobutyl rubber stoppers meeting USP Class VI standards, supplied by Daikyo Seiko, Ltd. or West Pharmaceutical Services. [8]
    • Syringes: Prefilled syringe components, if applicable, from Becton Dickinson (BD) or Gerresheimer AG.

What are the Regulatory and Quality Control Requirements?

Pfizerpen’s supply chain must adhere to stringent global regulatory standards to ensure product safety, efficacy, and quality.

• Good Manufacturing Practices (GMP): All manufacturing sites for raw materials, APIs, and finished drug products must comply with current GMP guidelines (cGMP) as defined by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other relevant health authorities.
• ICH Guidelines: Compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines is mandatory, particularly:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q10: Pharmaceutical Quality System.
  • ICH Q11: Development and Manufacture of Drug Substances.
• Quality Agreements: Formal Quality Agreements must be established with all critical suppliers. These agreements define roles, responsibilities, and specific quality standards, including:
  • Change control procedures.
  • Deviation and CAPA management.
  • Auditing rights.
  • Specification limits and testing protocols.
• Supply Chain Audits: Pfizer will conduct rigorous supplier qualification and ongoing audits to verify compliance with cGMP and internal quality standards. An audit failure can lead to immediate termination of a supplier relationship.
• Supply Chain Security: Measures to prevent counterfeiting and diversion, including serialization and track-and-trace capabilities, are essential as per the Drug Supply Chain Security Act (DSCSA) in the U.S. and similar regulations globally.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The global nature of pharmaceutical supply chains presents several inherent risks. For Pfizerpen, these include:

• Geopolitical Instability and Trade Wars: Reliance on suppliers in regions subject to political unrest or trade disputes can disrupt raw material flow.
  • Mitigation: Diversify sourcing across different geographic regions. Maintain safety stock of critical raw materials.
• Single Source Dependence: Over-reliance on a single supplier for a critical intermediate or excipient creates vulnerability.
  • Mitigation: Qualify and maintain at least two qualified suppliers for all critical components. Establish robust secondary supplier agreements.
• Quality Deviations and Recalls: Non-compliance with GMP or unexpected quality issues can lead to production halts and product recalls.
  • Mitigation: Implement stringent supplier quality management systems, including regular audits and performance monitoring. Ensure clear communication protocols for deviations.
• Capacity Constraints: Sudden increases in demand or unexpected shutdowns at key manufacturing facilities can lead to shortages.
  • Mitigation: Proactive capacity planning with suppliers. Secure long-term supply agreements with guaranteed capacity allocations.
• Logistics and Transportation Disruptions: Global shipping delays, port congestion, or extreme weather events can impact delivery timelines.
  • Mitigation: Utilize multiple logistics providers. Explore alternative transportation routes. Build buffer time into supply chain planning.
• Intellectual Property Infringement: While less common with established suppliers, there is a risk of IP leakage or unauthorized manufacturing.
  • Mitigation: Strict confidentiality agreements and robust IP protection clauses in all supplier contracts. Conduct due diligence on supplier IP handling procedures.

Key Takeaways

• Pfizerpen's supply chain involves complex organic intermediates, specialized reagents, and advanced sterile manufacturing capabilities.
• Dual-sourcing for API manufacturing is a critical strategy, involving both internal Pfizer sites and leading global CMOs like Lonza, Catalent, and WuXi AppTec.
• Excipients and packaging materials must meet stringent pharmaceutical-grade specifications, with suppliers like JRS Pharma, DuPont, SCHOTT AG, and West Pharmaceutical Services being key considerations.
• Strict adherence to cGMP and ICH guidelines is paramount across the entire supply chain.
• Mitigation strategies for supply chain risks must focus on diversification, robust quality agreements, proactive capacity planning, and secure logistics.

Frequently Asked Questions

1. What is the current status of Pfizerpen's clinical trials and projected market launch timeline? Pfizerpen is currently in [specify phase, e.g., Phase 3] clinical trials for [indication]. The projected market launch timeline is anticipated for [specify year, e.g., 2025], contingent upon successful trial outcomes and regulatory approvals.
2. Are there any known shortages or supply chain bottlenecks for the identified key raw materials? As of [current month, year], there are no widely reported significant global shortages impacting the primary raw material classes identified for Pfizerpen. However, ongoing monitoring of specific chemical precursor markets is advised due to inherent volatility.
3. What is Pfizer's approach to qualifying and auditing its pharmaceutical suppliers? Pfizer employs a comprehensive supplier qualification program that includes a detailed risk assessment, on-site audits for GMP compliance and quality systems, and evaluation of manufacturing capabilities and financial stability. Ongoing performance monitoring and periodic re-audits are standard practice.
4. Can the patent landscape for Pfizerpen's API synthesis intermediates impact supplier selection? Yes, the patent landscape for key synthesis intermediates is a critical factor. Pfizer will ensure all selected suppliers operate without infringing on existing patents, or that necessary licenses are secured, to prevent future legal challenges that could disrupt supply.
5. What measures are in place to ensure the cold chain integrity for temperature-sensitive Pfizerpen components or the final product? For temperature-sensitive components or the finished drug product, Pfizer will implement a robust cold chain management system. This includes utilizing validated cold chain packaging, temperature-monitoring devices throughout transit, and partnering with logistics providers specializing in cold chain transportation and storage.

---

Citations

[1] U.S. Food & Drug Administration. (2023). Manufacturer and Facility Information. Retrieved from [FDA website URL for facility lookup if publicly available, otherwise note source type] [2] Pfizer Inc. (2022). Annual Report 2022. [3] Lonza Group AG. (2023). Product & Services Overview. Retrieved from [Lonza website URL] [4] Catalent, Inc. (2023). Drug Substance Solutions. Retrieved from [Catalent website URL] [5] WuXi AppTec Co., Ltd. (2023). API Development & Manufacturing. Retrieved from [WuXi AppTec website URL] [6] Thermo Fisher Scientific. (2023). Lyophilization Services. Retrieved from [Thermo Fisher website URL] [7] Recipharm. (2023). Aseptic Filling. Retrieved from [Recipharm website URL] [8] West Pharmaceutical Services, Inc. (2023). Product Portfolio. Retrieved from [West Pharma website URL]